AnHorn Medicines is a novel drug discovery platform company with a strong pipeline, offering therapies that target and degrade disease-causing proteins. Our mission is to develop new class of BIGPRO® (Bi-functional liGand induced PROteolysis) drugs under the foundation of Targeted Protein Degradation (TPD), to address a broad range of life-threatening and life-impairing diseases.

Ascendo was established in October 2018. It is an offshore company registered in the Cayman Islands, U.K., and a start-up focusing on using translational sciences as its core energy to develop new drugs in immunotherapy. Ascendo has a first-in-class novel monoclonal antibody drug ASD141 that targets cancers and infections. It also has an unique therapeutic/preventive vaccine platform - ASD25X.

Vacino Biotech established in July 2020 focuses on developing the products of universal vaccine and nucleic acid medicine. Dr. Jia-Ming Chang was appointed as CEO and led the research to productize the flu and COVID vaccine with the state-of-the-art universal technology and the microRNA therapeutic toward clinical application.

iAnalyzer Inc. was founded in April 2021, with the goal of developing portable analytical instruments to meet the needs of real-time and on-the-spot measurement.

LumiSTAR Biotechnology focuses on development of various drug screening platforms for pharmaceutical and CRO companies. We have been committed to accelerate drug development process. Our core technologies are various optical genetically-encoded reporters (with different detection dynamic ranges), which can be incorporated with iPSC or disease-model cell lines for real-time monitoring how the cellular physiology influenced by testing drugs. LumiSTAR’s drug screening platform can apply on phenotypic screening, drug discovery, toxicity testing, and precision/personalized medicine.

SYNCELL is building a novel spatial biology system, Microscoop™, the world’s first in-cell “pickable” high-content microscope-based platform. The system leverages AI-based pattern-recognition algorithm to selectively harvest proteins and nucleic acids in situ from user-defined areas of interest.

Based on the professional field of specialty healthcare in rare diseases, Excelsior Biopharma has been engaged in the development the awareness of rare diseases, poisoning intoxication, and specific diseases, distribution of orphan drugs for more than 20 years of experience.

GWOXI was established in 2004 as a biotech new drug company based on stem cell technology. Apply stem cell technology to regenerative medicine and health care to develop testing service and new drug products.

JUNZHI is a biotechnology team from Taiwan, and we have established research and development centers and Operations Center in National Biotechnology Research Park and Tainan Science Park respectively.

Zheng Yang Biomedical Technology Co., Ltd. (ZYBT) is a new drug development company, dedicated to the research and development of Elate Ocular™ dry eye biologics and new drugs.

Mello Biotech is a research company specializes in development and commercialization of microRNA and stem cell technologies.

Nebulum Technologies is a start-up company focusing on the development of 3D pathology imaging technologies, with the goal of providing more comprehensive and accurate information for drug development and disease diagnosis.

Founded in 2014, Molsentech is dedicated to developing a biomedical platform that facilitates the non-invasive and real-time detection of minimum pathogens for patients.

VMIC provides integrated medicinal chemistry research with well-established drug research platform technologies to support the small molecule drug discovery projects for the biotechnology companies and academic/research/medical institutes in Taiwan or even the foreign companies.

Exland Biotechnology Inc. manufactures, supplied, and exports functional plant extracts in Taiwan for the past 12 years. Our R&D team is staffed with the most experienced experts in traditional herbs and plants.

Alps Biotechnology is a biotech company whose main goal is to develop new drugs and whose focus is the research of natural products and biochemistry. It has persistently committed to the development of new drugs and test reagents, as well as the research and development of healthy products. Alps Biotech also provides various professional technology services, such as protein separation, purification, and identification.

Sinew Pharma has six major products in two applications on hepatotoxicity-free acetaminophen (AAP) and fatty liver disease. Sinew Pharma, established in Taipei, Taiwan in 2014, is a new biopharmaceutical company with a focus on integrated new drug R&D.

At WinLux Biomedicine Technology Co., Ltd., a subsidiary of Chainwin Agriculture and Animal Technology Global Business Group, we strive to set the standard for quality, safety, and value in the discovery, research, and development in the healthcare industry.

VITAE Biomedical Co. Ltd. is a molecular screening technology company focused on innovation and leading, providing the most valuable molecular screening technology for cancer and other diseases.

The research team of Agari Phama consists of the experts from I-MEI FOODS CO., LTD and LOHAS BIOTECH DEVELOPMENT CORP. Base on the toxin and metal free agaricus blazei murill planted by unique AI-controlling planting approach, we further concentrated on developing botanical drugs from it.

Immunwork, Inc. was founded in 2014. We focus on the research, development, and commercialization of novel drugs to fulfill unmet medical needs. Our drugs are created based on our proprietary technology platform for treating multiple types of cancer, diabetes, obesity, non-alcoholic steatohepatitis (NASH), pathological blood clots, and other selected severe clinical conditions.

Bio Preventive Medicine Corp. (BPM) is a clinical-staged biotech company, we translate clinically validated and IP-protected biomarkers into precision diagnostic solutions for unmet clinical needs.

CHO PHARMA INC. was founded in 2013. As a pioneer in innovative glycotechnology and carbohydrate new drug development, we are devoted in providing better solutions for severe human diseases.

AcadeMab Biomedical Inc. established in 2020.
．Have competitive antibody drug research and development technology platform.
．Independently develop new antibody drugs.
．Become a world-class antibody new drug research and development company.

PharmaEssentia Corporation (TPEx: 6446) is a fully integrated biotech company based in Taiwan. The company engages in innovation, clinical development, production and manufacturing of new drugs, and global commercialization.

OBI is a Taiwan-based biopharma company founded in 2002 with the headquarter in Taipei and subsidiaries in the United States, China, Hong Kong and Australia. Our mission is to improve health and the quality of life of patients through innovative cancer therapeutics. We seek to develop and license novel therapeutic agents for unmet medical needs against cancers by targeting the Globo Series antigens (Globo H, SSEA-4), the AKR1C3 enzyme, and other promising targets.

With the goal of developing innovative drugs on a global scale, Oneness Biotech has established a value chain for the research and development of new drugs independently, namely R (research), D (development), C (clinical), and M (Marketing). This includes the professional R&D teams and technologies for different domains such as the establishment of a technology platform, CMC (chemistry, manufacturing, and controls), pharmacology/toxicology, pharmacokinetics/toxicokinetics, clinical pharmacology/pharmacokinetics, and clinical medicine.

CellMax Life is a molecular diagnostics company revolutionizing early cancer detection with a proprietary bio-mimetic technology platform that enables detection of pre-cancer & cancer cells in blood.

GenomeFrontier addresses the unmet needs of conventional virus and/or virus-free gene-modified cell therapy by integrating four platforms: Quantum Nufect™, Quantum pBac™, iCellar™ and G-Tailor™, which improve vector delivery, therapeutic gene integration, cell expansion capacity and gene design, respectively. Synergistically, these platforms form the Quantum Engine™, with patent protection ensured in major countries, for production of virus-free, gene-modified cells optimal for therapy.

LuminX Biotech dedicates to accelerate the optimization of cell-therapy-products through specific understanding of therapeutic cells distribution in-vivo, long-term viability, as well as their biological fate either in preclinical or clinical setting and our technologies can transition a potential therapy from the research stage to advanced clinical and commercial applications to save lives.

Ochre Bio, HQ’d in Oxford UK, develops genomic medicines that rejuvenate transplanted livers, ultimately with the goal of applying these therapies to treat fatty liver disease (NASH/NAFL) and other metabolic diseases. Ochre Bio Taiwan is Ochre’s first overseas research site, focusing on Target Discovery and Target Validation. The site will employ single-cell and spatial sequencing, advanced genomics, and high-throughput screening to identify disease-causing genes, and develop combination therapies together with Oxford HQ. In Jan 2021, Ochre Bio completed the largest genomic atlas of the liver, and is currently progressing multiple GalNAc-siRNA candidates toward the clinic.

NanoRay Biotech Co., Ltd. is an innovative company devoted to the research and development of new-generation transmission type X-ray tube. The X-ray technology is applied in cancer treatment, medical image diagnosis, and industrial examination.

Anbogen Therapeutics (ABT) is a clinical stage biopharmaceutical company founded in 2019, based in Taipei, Taiwan and focused on developing first/best-in-class precision oncology medicines. We target cancer patients having driver gene mutations with the greatest unmet therapeutic needs. Founders and the executive team deeply rooted in science and with extensive experience in medicinal chemistry, drug discovery and clinical development.

National Biotechnology Research Park (NBRP) was opened in Oct. 2018, and is committed to stimulate and promote valuable and effective biotechnology research in Taiwan. NBRP provides the first ecosystem platform for biomedical research on a national level. With the joint participation of industry, government, universities and national research labs, the NBRP aims to accelerate completion timelines for new drug development, with the ultimate goal of enhancing human health and welfare.

In collaboration with different ministries of Taiwan Government, BioHub Taiwan was established at NBRP. The major goal of BioHub Taiwan is to push impactful fundamental research into commercialization. Our mission is to integrate resources among the Government, Academics, and Industries to provide one stop solution. BioHub Taiwan combines Academia Sinica’s preeminent research capacities and the seven core facilities to support innovative R&D. BioHub Taiwan also integrates interdisciplinary resources into the NBRP Academy to cultivate business talents and provide business mentoring. BioHub Taiwan welcome the installation of domestic and international partners, investors and venture capitals to station at NBRP to maximize the opportunities of networking and partnering.

To facilitate the development of biomedical translational research in Taiwan, the National Biotechnology Research Park (hereafter referred to as “the NBRP”) established the BioHub Taiwan to provide an adequate environment that can enable biomedical translational research related research and development (R&D) teams and companies to participate in cooperation projects for developing new biopharmaceutical drugs. The ultimate objectives are to increase the effectiveness of innovative incubation technology, expedite the development of innovation and technology companies, and upgrade relevant industries in Taiwan.